Question 12. Do you think that the low conductance of many types of ion channels has been a major barrier to both their study and the
identification of selective modulators?
Question 13. How has your organization's level of activity changed in the past five years in terms of developing ion channel modulators?
Question 14. Does your organization plan to change its level of involvement with ion channels over the next three years?
Question 15. Do you have any additional observations about the discovery and development of ion channel modulators?
COMPANY INDEX WITH WEB ADDRESSES 149
Table 2.1. Families of Ion Channels
Table 2.2. Voltage-Gated Calcium Channels
Table 2.3. Old and New Nomenclatures of Glutamate-Gated Ion Channels
Table 4.1. L-Type Calcium Channel Blockers and 2007 Sales
Table 4.2. KATP Channel Modulators and 2007 Sales
Table 4.3. GABAA Channel Modulators and 2007 Sales
Table 4.4. Class I Antiarrhythmic Agents (Sodium Channel Blockers)
Table 4.5. Class III Antiarrhythmic Agents (Potassium Channel Blockers)
Table 4.6. Anticonvulsant Agents and 2007 Sales
Table 4.7. 5-HT3 Antagonists and 2007 Sales
Table 5.1. Ion Channel Modulators Awaiting Regulatory Approval
Table 5.2. Ion Channel Modulators in Phase III Studies
Table 5.3. Ion Channel Modulators in Phase II Studies for CNS Disorders
Table 5.4. Ion Channel Modulators for Non-CNS Conditions in Phase II Studies
Table 5.5. Ion Channel Modulators in Phase I Studies
Figure 5.1. Ion Channels Modulators in Development by Major Pharmaceutical Companies
Figure 5.2. Ion Channel Modulators in Development by Target
Copyright©2009 PR Newswire.
All rights reserved